Semaglutide and Risk of NAION in Type 2 Diabetes
Author Information
Author(s): Jakob Grauslund, Andreas Abou Taha, Laleh Dehghani, Ryo Kawasaki, Sören Möller, Kurt Højlund, Lonny Stokholm
Primary Institution: Odense University Hospital
Hypothesis
Does exposure to once-weekly semaglutide increase the risk of nonarteritic anterior ischemic optic neuropathy (NAION) in patients with type 2 diabetes?
Conclusion
The use of once-weekly semaglutide more than doubles the risk of NAION in patients with type 2 diabetes.
Supporting Evidence
- Semaglutide exposure was associated with a higher incidence rate of NAION (0.228 vs. 0.093 per 1000 person-years).
- 67 persons exposed to semaglutide developed NAION with a median time from first prescription to event of 22.2 months.
- The hazard ratio for NAION among semaglutide users was 2.19 after adjusting for multiple factors.
- Overall, 218 persons developed NAION during 1,915,120 person-years of observation.
Takeaway
If you take a medicine called semaglutide for diabetes, it might make you more likely to have a serious eye problem that can cause vision loss.
Methodology
A five-year longitudinal cohort study was conducted using national registers to evaluate the risk of NAION in persons with type 2 diabetes exposed to semaglutide.
Potential Biases
Potential unmeasured confounding factors may exist, and the study cannot claim a causal relationship due to the observational nature.
Limitations
The study could not assess smoking, blood pressure, or body mass index, and relied on diagnostic codes without direct ophthalmic examinations.
Participant Demographics
Median age was 65 years, with 54.5% male participants.
Statistical Information
P-Value
p<0.001
Confidence Interval
95% CI 1.54−3.12
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website